<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Cardiovascular disease: prevention: hypertension; Hypertension; Cardiovascular disease: prevention: non-drug treatment; Cardiovascular disease: prevention: obesity; Hypertension: elderly; Elderly: hypertension in; Hypertension: systolic; Hypertension: diabetes; Cardiovascular disease: prevention: diabetes; Hypertension: renal disease; Hypertension: pregnancy; Pregnancy: hypertension in; Pre-eclampsia; Hypertensive crises; Hypertension: crises" /><meta name="IX" content="Cardiovascular disease: prevention: hypertension; Cardiovascular disease: prevention: non-drug treatment; Cardiovascular disease: prevention: obesity; Hypertension: elderly; Elderly: hypertension in; Hypertension: systolic; Hypertension: diabetes; Cardiovascular disease: prevention: diabetes; Hypertension: renal disease; Hypertension: pregnancy; Pregnancy: hypertension in; Pre-eclampsia; Hypertensive crises; Hypertension: crises" /><meta name="IXM" content="Hypertension" /><title>2.5 Hypertension and heart failure: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1034-hypertension-and-heart-failure.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1034-hypertension-and-heart-failure.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP1034-hypertension-and-heart-failure.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 12 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1025-timolol-maleate.htm" title="Previous: TIMOLOL MALEATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1040-vasodilator-antihypertensive-drugs.htm" title="Next: 2.5.1 Vasodilator antihypertensive drugs">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1><span>2.5 </span>Hypertension and heart failure</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div><h2>Hypertension</h2><p>Lowering raised blood pressure decreases the risk of stroke, coronary events, heart failure, and renal impairment. Advice on antihypertensive therapy in this section takes into account the recommendations of the Joint British Societies (JBS2: British Societies' guidelines on prevention of cardiovascular disease in clinical practice. <em>Heart</em> 2005; <strong>91</strong> (Suppl V): v1–v52) and NICE clinical guidance 127 (August 2011), Hypertension—Clinical management of primary hypertension in adults.</p><p>Possible causes of hypertension (e.g. renal disease, endocrine causes), contributory factors, risk factors, and the presence of any complications of hypertension, such as left ventricular hypertrophy, should be established. Patients should be given advice on lifestyle changes to reduce blood pressure or cardiovascular risk; these include smoking cessation, weight reduction, reduction of excessive intake of alcohol and caffeine, reduction of dietary salt, reduction of total and saturated fat, increasing exercise, and increasing fruit and vegetable intake.</p></div><div><h2>Thresholds and targets for treatment</h2><p>Patients presenting with a blood pressure of 140/90 mmHg or higher when measured in a clinic setting, should be offered ambulatory blood pressure monitoring (or home blood pressure monitoring if ambulatory blood pressure monitoring is unsuitable) to confirm the diagnosis and stage of hypertension.</p><p>Stage 1 hypertension:</p><ul><li><p>Clinic blood pressure 140/90 mmHg or higher, <em>and</em> ambulatory daytime average or home blood pressure average 135/85 mmHg or higher</p> </li><li><p>Treat patients under 80 years who have stage 1 hypertension and target-organ damage (e.g. left ventricular hypertrophy, chronic kidney disease, hypertensive retinopathy), cardiovascular disease, renal disease, diabetes, or a 10 year cardiovascular risk ≥ 20%<cite><a href="PHP1034-hypertension-and-heart-failure.htm#ID0EDBAFIAA" class="tooltip ID0EDBAFIAA">(1)</a></cite>; in the absence of these conditions, advise lifestyle changes and review annually. For patients under 40 years with stage 1 hypertension but <strong>no</strong> overt target-organ damage, cardiovascular disease, renal disease, or diabetes, consider seeking specialist advice for evaluation of secondary causes of hypertension</p> </li></ul><p>Stage 2 hypertension:</p><ul><li><p>Clinic blood pressure 160/100 mmHg or higher, <em>and</em> ambulatory daytime average or home blood pressure average 150/95 mmHg or higher</p> </li><li><p>Treat all patients who have stage 2 hypertension, regardless of age</p> </li></ul><p>Severe hypertension:</p><ul><li><p>Clinic systolic blood pressure ≥ 180 mmHg <em>or</em> clinic diastolic blood pressure ≥ 110 mmHg; treat promptly—see <a title="BNF:target-block: Hypertensive crises" href="PHP1034-hypertension-and-heart-failure.htm#PHP1039">Hypertensive Crises</a></p> </li></ul><p>A target clinic blood pressure below 140/90 mmHg is suggested for patients under 80 years; a target ambulatory or home blood pressure average (during the patient’s waking hours) of below 135/85 mmHg is suggested for patients under 80 years; see also Hypertension in the Elderly, below. A target clinic blood pressure below 130/80 mmHg should be considered for those with established atherosclerotic cardiovascular disease, or diabetes in the presence of kidney, eye, or cerebrovascular disease. In some individuals it may not be possible to reduce blood pressure below the suggested targets despite the use of appropriate therapy.</p></div><div id="PHP1035"><h2>Drug treatment of hypertension</h2><p>A single antihypertensive drug is often inadequate in the management of hypertension, and additional antihypertensive drugs are usually added in a step-wise manner until control is achieved. Unless it is necessary to lower the blood pressure urgently (see Hypertensive Crises, below), an interval of at least 4 weeks should be allowed to determine response; clinicians should ensure antihypertensive drugs are titrated to the optimum or maximum tolerated dose at each step of treatment. Response to drug treatment may be affected by age and ethnicity.</p><p><strong>Patients under 55 years:</strong></p><p>Step 1</p><ul><li><p><strong>ACE inhibitor</strong> (<a title="BNF:sub-sub-section: Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>); if not tolerated, offer an <strong>angiotensin-II receptor antagonist</strong> (<a title="BNF:sub-sub-section: Angiotensin-II receptor antagonists" href="PHP1205-angiotensin-ii-receptor-antagonists.htm">section 2.5.5.2</a>). If both ACE inhibitors and angiotensin-II receptor antagonists are contra-indicated or not tolerated, consider a <strong>beta-blocker</strong> (<a title="BNF:section: Beta-adrenoceptor blocking drugs" href="PHP934-beta-adrenoceptor-blocking-drugs.htm">section 2.4</a>); beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or at high risk of developing diabetes</p> </li></ul><p>Step 2</p><ul><li><p>ACE inhibitor or angiotensin-II receptor antagonist in combination with a <strong>calcium-channel blocker</strong> (<a title="BNF:sub-section: Calcium-channel blockers" href="PHP1309-calcium-channel-blockers.htm">section 2.6.2</a>). If a calcium-channel blocker is not tolerated or if there is evidence of, or a high risk of, heart failure, give a <strong>thiazide-related diuretic</strong> (e.g. chlortalidone or indapamide) (<a title="BNF:sub-section: Thiazides and related diuretics" href="PHP772-thiazides-and-related-diuretics.htm">section 2.2.1</a>). If a beta-blocker was given at Step 1, add a calcium-channel blocker in preference to a thiazide-related diuretic (see Step 1 above)</p> </li></ul><p>Step 3</p><ul><li><p>ACE inhibitor or angiotensin-II receptor antagonist in combination with a calcium-channel blocker <em>and</em> a thiazide-related diuretic </p> </li></ul><p>Step 4 (resistant hypertension)</p><ul><li><p>Consider seeking specialist advice</p> </li><li><p>Add low-dose <strong>spironolactone</strong> (<a title="BNF:monograph: SPIRONOLACTONE" href="PHP834-spironolactone.htm">section 2.2.3</a>) [unlicensed indication], <em>or</em> use high-dose thiazide-related diuretic if plasma-potassium concentration above 4.5 mmol/litre</p> </li><li><p>Monitor renal function and electrolytes</p> </li><li><p>If additional diuretic therapy is contra-indicated, ineffective, or not tolerated, consider an <strong>alpha-blocker</strong> (<a title="BNF:sub-section: Alpha-adrenoceptor blocking drugs" href="PHP1088-alpha-adrenoceptor-blocking-drugs.htm">section 2.5.4</a>) <em>or</em> a beta-blocker </p> </li></ul><p><strong>Patients over 55 years, and patients of any age who are of African or Caribbean family origin:</strong></p><p>Step 1</p><ul><li><p>Calcium-channel blocker; if not tolerated or if there is evidence of, or a high risk of, heart failure, give a thiazide-related diuretic (e.g. chlortalidone or indapamide)</p> </li></ul><p>Step 2</p><ul><li><p>Calcium-channel blocker <em>or</em> thiazide-related diuretic in combination with an ACE inhibitor or angiotensin-II receptor antagonist (an angiotensin-II receptor antagonist in combination with a calcium-channel blocker is preferred in patients of African or Caribbean family origin)</p> </li></ul><p>Steps 3 and 4</p><ul><li><p>Treat as for patients under 55 years (see above)</p> </li></ul></div><div id="PHP1036"><h2>Other measures to reduce cardiovascular risk</h2><p><strong>Aspirin</strong> (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) in a dose of 75 mg daily reduces the risk of cardiovascular events and myocardial infarction. Unduly high blood pressure must be controlled before aspirin is given. Unless contra-indicated, aspirin is recommended for all patients with established cardiovascular disease. Use of aspirin in primary prevention, in those with or without diabetes, is of unproven benefit (see also <a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>).</p><p>Lipid-regulating drugs can also be of benefit in cardiovascular disease or in those who are at high risk of developing cardiovascular disease (<a title="section: Lipid-regulating drugs" href="PHP1621-lipid-regulating-drugs.htm">section 2.12</a>).</p></div><div id="PHP1037"><h2>Hypertension in the elderly</h2><p>Benefit from antihypertensive therapy is evident up to at least 80 years of age, but it is probably inappropriate to apply a strict age limit when deciding on drug therapy. Patients who reach 80 years of age while taking antihypertensive drugs should continue treatment, provided that it continues to be of benefit and does not cause significant side-effects. If patients are aged over 80 years when diagnosed with stage 1 hypertension, the decision to treat should be based on the presence of other co-morbidities; patients with stage 2 hypertension should be treated as for patients over 55 years (see above). A target clinic blood pressure below 150/90 mmHg is suggested for patients over 80 years; the suggested target ambulatory or home blood pressure average (during the patient’s waking hours) is below 145/85 mmHg.</p></div><div><h2>Isolated systolic hypertension</h2><p>Isolated systolic hypertension (systolic pressure ≥ 160 mmHg, diastolic pressure &lt; 90 mmHg) is common in patients over 60 years, and is associated with an increased cardiovascular disease risk; it should be treated as for patients with both a raised systolic and diastolic blood pressure (see above). Patients with severe postural hypotension should be referred to a specialist.</p></div><div><h2>Hypertension in diabetes</h2><p>For patients with diabetes, a target clinic blood pressure below 140/80 mmHg is suggested (below 130/80 mmHg is advised if kidney, eye, or cerebrovascular disease are also present). However, in some individuals, it may not be possible to achieve this level of control despite appropriate therapy. Most patients require a combination of antihypertensive drugs.</p><p>Hypertension is common in type 2 diabetes, and antihypertensive treatment prevents macrovascular and microvascular complications. In type 1 diabetes, hypertension usually indicates the presence of diabetic nephropathy. An ACE inhibitor (or an angiotensin-II receptor antagonist) may have a specific role in the management of diabetic nephropathy (<a title="topic: Diabetic nephropathy" href="PHP4233-diabetic-nephropathy.htm">section 6.1.5</a>); in patients with type 2 diabetes, an ACE inhibitor (or an angiotensin-II receptor antagonist) can delay progression of microalbuminuria to nephropathy.</p></div><div><h2>Hypertension in renal disease</h2><p>A target clinic blood pressure below 140/90 mmHg is suggested (below 130/80 mmHg is advised in patients with chronic kidney disease and diabetes, or if proteinuria exceeds 1 g in 24 hours). An ACE inhibitor (or an angiotensin-II receptor antagonist) should be considered for patients with proteinuria; however, ACE inhibitors should be used with caution in renal impairment, see <a title="target-block: ACE inhibitors renal effects" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#PHP1128">section 2.5.5.1</a>. Thiazide diuretics may be ineffective and high doses of loop diuretics may be required.</p></div><div id="PHP1038"><h2>Hypertension in pregnancy</h2><p>Hypertensive complications in pregnancy can be hazardous for both the mother and the fetus, and are associated with a significant risk of morbidity and mortality; complications can occur in pregnant women with pre-existing chronic hypertension, or in those who develop hypertension in the latter half of pregnancy.</p><p><strong>Labetalol</strong> (<a title="monograph: LABETALOL HYDROCHLORIDE" href="PHP989-labetalol-hydrochloride.htm">section 2.4</a>) is widely used for treating hypertension in pregnancy. <strong>Methyldopa</strong> (<a title="monograph: METHYLDOPA" href="PHP1077-methyldopa.htm">section 2.5.2</a>) is considered safe for use in pregnancy. Modified-release preparations of <strong>nifedipine</strong> [unlicensed] are also used, but see <a title="BNF:monograph: NIFEDIPINE" href="PHP1353-nifedipine.htm">section 2.6.2</a> for warnings on use during pregnancy.</p><p>The following advice takes into account the recommendations of NICE Clinical Guideline 107 (August 2010), Hypertension in Pregnancy.</p><p>Pregnant women with chronic hypertension who are already receiving antihypertensive treatment should have their drug therapy reviewed. In uncomplicated chronic hypertension, a target blood pressure of &lt;150/100 mmHg is recommended; women with target-organ damage as a result of chronic hypertension, and in women with chronic hypertension who have given birth, a target blood pressure of &lt;140/90 mmHg is advised. Long-term antihypertensive treatment should be reviewed 2 weeks following the birth. Women managed with methyldopa during pregnancy should discontinue treatment and restart their original antihypertensive medication within 2 days of the birth.</p><p>Pregnant women are at high risk of developing pre-eclampsia if they have chronic kidney disease, diabetes mellitus, autoimmune disease, chronic hypertension, or if they have had hypertension during a previous pregnancy; these women are advised to take <strong>aspirin</strong> (<a title="BNF:monograph: ASPIRIN (antiplatelet)" href="PHP1531-aspirin-antiplatelet.htm">section 2.9</a>) in a dose of 75 mg once daily [unlicensed indication] from week 12 of pregnancy until the baby is born. Women with more than one moderate risk factor (first pregnancy, aged ≥40 years, pregnancy interval &gt;10 years, BMI ≥35 kg/m<sup>2</sup> at first visit, multiple pregnancy, or family history of pre-eclampsia) for developing pre-eclampsia are also advised to take aspirin 75 mg once daily [unlicensed indication] from week 12 of pregnancy until the baby is born.</p><p>Women with pre-eclampsia or gestational hypertension who present with a blood pressure over 150/100 mmHg, should receive initial treatment with oral labetalol to achieve a target blood pressure of &lt;150 mmHg systolic, and diastolic 80–100 mmHg. If labetalol is unsuitable, methyldopa or modified-release nifedipine may be considered. Women with gestational hypertension or pre-eclampsia who have been managed with methyldopa during pregnancy should discontinue treatment within 2 days of the birth. Women with a blood pressure of ≥160/110 mmHg who require critical care during pregnancy or after birth should receive immediate treatment with either oral or intravenous labetalol, intravenous hydralazine (<a title="BNF:monograph: HYDRALAZINE HYDROCHLORIDE" href="PHP1048-hydralazine-hydrochloride.htm">section 2.5.1</a>), or oral modified-release nifedipine to achieve a target blood pressure of &lt;150 mmHg systolic, and diastolic 80–100 mmHg.</p><p>For use of magnesium sulfate in pre-eclampsia and eclampsia, see <a title="target-block: eclampsia and preeclampsia target block" href="PHP6109-magnesium.htm#PHP6114">section 9.5.1.3</a>.</p></div><div id="PHP1039"><h2>Hypertensive crises</h2><p>If blood pressure is reduced too quickly in the management of hypertensive crises, there is a risk of reduced organ perfusion leading to cerebral infarction, blindness, deterioration in renal function, and myocardial ischaemia.</p><p>A <em>hypertensive emergency</em> is defined as severe hypertension with acute damage to the target organs (e.g. signs of papilloedema or retinal haemorrhage, or the presence of clinical conditions such as acute coronary syndromes, acute aortic dissection, acute pulmonary oedema, hypertensive encephalopathy, acute cerebral infarction, intracerebral or subarachnoid haemorrhage, eclampsia, or rapidly progressing renal failure); prompt treatment with intravenous antihypertensive therapy is generally required. Over the first few minutes or within 2 hours, blood pressure should be reduced by 20–25%. When intravenous therapy is indicated, treatment options include sodium nitroprusside [unlicensed] (<a title="BNF:monograph: SODIUM NITROPRUSSIDE" href="PHP1065-sodium-nitroprusside.htm">section 2.5.1</a>), labetalol (<a title="BNF:monograph: LABETALOL HYDROCHLORIDE" href="PHP989-labetalol-hydrochloride.htm">section 2.4</a>), glyceryl trinitrate (<a title="BNF:monograph: GLYCERYL TRINITRATE" href="PHP1258-glyceryl-trinitrate.htm">section 2.6.1</a>), phentolamine (<a title="BNF:monograph: PHENTOLAMINE MESILATE" href="PHP1120-phentolamine-mesilate.htm">section 2.5.4</a>), hydralazine (<a title="BNF:monograph: HYDRALAZINE HYDROCHLORIDE" href="PHP1048-hydralazine-hydrochloride.htm">section 2.5.1</a>), or esmolol (<a title="BNF:monograph: ESMOLOL HYDROCHLORIDE" href="PHP987-esmolol-hydrochloride.htm">section 2.4</a>); choice of drug is dependent on concomitant conditions and clinical status of the patient.</p><p>Severe hypertension (blood pressure ≥180/110 mmHg) without acute target-organ damage is defined as a <em>hypertensive urgency</em>; blood pressure should be reduced gradually over 24–48 hours with oral antihypertensive therapy, such as labetalol, or the calcium-channel blockers (<a title="BNF:sub-section: Calcium-channel blockers" href="PHP1309-calcium-channel-blockers.htm">section 2.6.2</a>) amlodipine, felodipine, or isradipine. Use of sublingual nifedipine is not recommended.</p><p>For advice on short-term management of hypertensive episodes in phaeochromocytoma, see under Phaeochromocytoma, <a title="monograph-family: Phaeochromocytoma" href="PHP1116-phaeochromocytoma.htm">section 2.5.4</a>.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1040-vasodilator-antihypertensive-drugs"><a href="PHP1040-vasodilator-antihypertensive-drugs.htm" title="2.5.1 Vasodilator antihypertensive drugs">2.5.1 Vasodilator antihypertensive drugs</a></li><li id="_PHP1071-centrally-acting-antihypertensive-drugs"><a href="PHP1071-centrally-acting-antihypertensive-drugs.htm" title="2.5.2 Centrally acting antihypertensive drugs">2.5.2 Centrally acting antihypertensive drugs</a></li><li id="_PHP1084-adrenergic-neurone-blocking-drugs"><a href="PHP1084-adrenergic-neurone-blocking-drugs.htm" title="2.5.3 Adrenergic neurone blocking drugs">2.5.3 Adrenergic neurone blocking drugs</a></li><li id="_PHP1088-alpha-adrenoceptor-blocking-drugs"><a href="PHP1088-alpha-adrenoceptor-blocking-drugs.htm" title="2.5.4 Alpha-adrenoceptor blocking drugs">2.5.4 Alpha-adrenoceptor blocking drugs</a></li><li id="_PHP1122-drugs-affecting-the-renin-angiotensin-system"><a href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm" title="2.5.5 Drugs affecting the renin-angiotensin system">2.5.5 Drugs affecting the renin-angiotensin system</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1025-timolol-maleate.htm">Previous: TIMOLOL MALEATE</a> | <a class="top" href="PHP1034-hypertension-and-heart-failure.htm#">Top</a> | <a accesskey="]" href="PHP1040-vasodilator-antihypertensive-drugs.htm">Next: 2.5.1 Vasodilator antihypertensive drugs</a> ►</div><ol class="cC"><li class="footnote" id="ID0EDBAFIAA"><p>Cardiovascular disease risk may be determined from the <a title="BNF:topic: How to use the Cardiovascular Risk Prediction Charts for Primary Prevention" href="PHP10418-how-to-use-the-cardiovascular-risk-prediction-charts-for-primary-prevention.htm">chart</a> issued by the Joint British Societies (<em>Heart</em> 2005; <strong>91</strong> (Suppl V): v1–v52). The Joint British Societies' ‘Cardiac Risk Assessor’ computer programme may also be used to determine cardiovascular disease risk.</p></li></ol></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>